血清LncRNA MIR155HG在慢性心力衰竭患者中的表达及临床意义
|
摘要
目的探讨LncRNA MIR155HG在慢性心力衰竭(CHF)患者血清中的表达及其作为慢性心力衰竭患者生物标志物的潜能。方法收集2016年1月至2018年01月我院收治的93例CHF患者(心功能Ⅰ级22例,Ⅱ级24例;Ⅲ级21例;Ⅳ级26例),同时收集同期健康体检者33例作为对照组,QRT-PCR检测血清MIR155HG的表达,分析MIR155HG的表达与临床病理参数的相关性及其作为生物标志物潜能。结果慢性心力衰竭患者血清中MIR155HG的表达水平(7. 755±0. 449)较健康对照组(1. 199±0. 218)显著升高,差异有统计学意义(P<0. 05); MIR155HG在心功能Ⅰ级～Ⅳ级的CHF患者中的表达水平逐渐升高,各组间差异有统计学意义(P<0. 05)。心肌梗死后重度左室重构患者血清MIR155HG的表达较无左室重构患者明显增高,差异有统计学意义(P<0. 05),在重度左室重构患者心肌梗死后早期(1-3个月) MIR155HG升高缓慢,随后开始持续升高,差异有统计学意义(P<0. 05)。而无论是缺血性还是非缺血性心力衰竭患者血清MIR155HG的表达均较心肌梗死后1年心室重构患者明显增高,差异有统计学意义(P<0. 05)。血清MIR155HG的表达与左室舒张末期容积呈正相关关系(r=0. 672,P<0. 001),与左室射血分数呈负相关关系(r=-0. 630,P<0. 001)。结论血清MIR155HG水平的高低与慢性心力衰竭具有一定的相关性,可以间接的反映心力衰竭的严重程度。
Objective To explore the expression ofserum LncRNAMIR155 HG in patients with chronic heart failure( CHF and its potential as biomarkers in patients with chronic heart failure.Methods 93 patients with CHF,from January 2016 to January 2018 in our hospital,were collected,including 22 casesin cardiac function Ⅰ class,24 cases in Ⅱ class,21 cases in Ⅲ class and26 case in Ⅳ Class,and at the same time,33 healthysubjects in the same period were collected as control group.Theexpression ofserum MIR155 HG was detected by QRT-PCR,and the correlation between the expression of MIR155 HG and clinicopathologic parameters and its potential as biomarkers were analyzed.Results The expression level of serum MIR155 HG in patients with chronic heart failure( 7. 755±0. 449) was significantly higher than that in the Healthy control group( 1. 199±0. 218),statistically significant( P<0. 05).The expression level of MIR155 HGincreased gradually in CHF patients with Ⅰ level to Ⅳlevel of heart function,statistically significant( P<0. 05).The expression of serum MIR155 HG in patients with severe left ventricular remodeling after myocardial infarction was significantly higher than that in patients without left ventricular remodeling,statistically significant( P<0. 05),and the MIR155 HG increased slowly in the early stage of myocardial infarction( 1-3 months) in patients with severe left ventricular remodeling,and then began to rise continuously,statistically significant( P< 0. 05). The expression of serum MIR155 HG in patients with ischemic or non-ischemic heart failure was significantly higher than that in patients with ventricular remodeling for 1 years after myocardial infarction,statistically significant( P<0. 05).The expression of serum MIR155 HG was positively correlated with the left ventricular end-diastolic volume( r = 0. 672,P < 0. 001) and negatively correlated with left ventricular ejection fraction( r =-0. 630,P<0. 001).Conclusion The serum MIR155 HG level has a certain correlation with chronic heart failure,and can indirectly reflect the severity of heart failure.
Objective To explore the expression ofserum LncRNAMIR155 HG in patients with chronic heart failure( CHF and its potential as biomarkers in patients with chronic heart failure.Methods 93 patients with CHF,from January 2016 to January 2018 in our hospital,were collected,including 22 casesin cardiac function Ⅰ class,24 cases in Ⅱ class,21 cases in Ⅲ class and26 case in Ⅳ Class,and at the same time,33 healthysubjects in the same period were collected as control group.Theexpression ofserum MIR155 HG was detected by QRT-PCR,and the correlation between the expression of MIR155 HG and clinicopathologic parameters and its potential as biomarkers were analyzed.Results The expression level of serum MIR155 HG in patients with chronic heart failure( 7. 755±0. 449) was significantly higher than that in the Healthy control group( 1. 199±0. 218),statistically significant( P<0. 05).The expression level of MIR155 HGincreased gradually in CHF patients with Ⅰ level to Ⅳlevel of heart function,statistically significant( P<0. 05).The expression of serum MIR155 HG in patients with severe left ventricular remodeling after myocardial infarction was significantly higher than that in patients without left ventricular remodeling,statistically significant( P<0. 05),and the MIR155 HG increased slowly in the early stage of myocardial infarction( 1-3 months) in patients with severe left ventricular remodeling,and then began to rise continuously,statistically significant( P< 0. 05). The expression of serum MIR155 HG in patients with ischemic or non-ischemic heart failure was significantly higher than that in patients with ventricular remodeling for 1 years after myocardial infarction,statistically significant( P<0. 05).The expression of serum MIR155 HG was positively correlated with the left ventricular end-diastolic volume( r = 0. 672,P < 0. 001) and negatively correlated with left ventricular ejection fraction( r =-0. 630,P<0. 001).Conclusion The serum MIR155 HG level has a certain correlation with chronic heart failure,and can indirectly reflect the severity of heart failure.
引文
[1]Mascherbauer J,Grünig,Ekkehard,Halank M,et al.Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction[J].Wiener klinische Wochenschrift,2016,128(23-24):882-889.
[2]Nobre TS,Antunes-Correa LM,Groehs RV,et al.Exercise Training Improves Neurovascular Control and Calcium Cycling Gene Expression in Heart Failure Patients with Cardiac Resynchronization Therapy[J].Am J Physiol Heart Circ Physiol,2016:ajpheart.00275.02016.
[3]Fu TC,Lin YC,Chang CM,et al.Validation of a new simple scale to measure symptoms in heart failure from traditional Chinese medicine view:a cross-sectional questionnaire study[J].BMC Complement Altern Med,2016,16(1):342.
[4]Hermans-Beijnsberger S,van Bilsen M,and Schroen BLong non-coding RNAs in the failing heart and vasculature[J].Noncoding RNA Res,2018,3(3):118-130.
[5]Zampetaki A,Albrecht A,and Steinhofel KLong Non-coding RNA Structure and Function:Is There a Link?[J].Front Physiol,2018,9:1201.
[6]Kataoka M,Wang DZ.Noncoding RNAs in Cardiovascular Disease[M]//Etiology and Morphogenesis of Congenital Heart Disease.Springer Japan,2016:313-317.
[7]Lu YW,Wang DZ.Non-coding RNA in Ischemic and Non-ischemic Cardiomyopathy[J].Curr Cardiol Rep,2018,20(11):115.
[8]Peters T,Hermans-Beijnsberger S,Beqqali A,et al.Long Non-Coding RNA Malat-1 Is Dispensable during Pressure Overload-Induced Cardiac Remodeling and Failure in Mice[J].PLoS One,2016,11(2):e0150236.
[9]Viereck J,Kumarswamy R,Foinquinos A,et al.Long noncoding RNAChast promotes cardiac remodeling[J].Sci Transl Med,2016,8(326):326ra322.
[10]Boeckel JN,Perret MF,Glaser SF,et al.Identification and regulation of the long non-coding RNA Heat2 in heart failure[J].J Mol Cell Cardiol,2018,126:13-22.
[11]Wang K,Long B,Zhou LY,et al.CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation[J].Nat Commun,2014,5:3596.
[12]Wang K,Liu F,Zhou LY,et al.The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489[J].Circ Res,2014,114(9):1377-1388.
[13]Leung A,Trac C,Jin W,et al.Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells[J].Circ Res,2013,113(3):266-278.
[14]Qiu JJ,Lin YY,Ding JX,et al.Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer[J].Int J Oncol,2015,46(6):2497-2505.
[2]Nobre TS,Antunes-Correa LM,Groehs RV,et al.Exercise Training Improves Neurovascular Control and Calcium Cycling Gene Expression in Heart Failure Patients with Cardiac Resynchronization Therapy[J].Am J Physiol Heart Circ Physiol,2016:ajpheart.00275.02016.
[3]Fu TC,Lin YC,Chang CM,et al.Validation of a new simple scale to measure symptoms in heart failure from traditional Chinese medicine view:a cross-sectional questionnaire study[J].BMC Complement Altern Med,2016,16(1):342.
[4]Hermans-Beijnsberger S,van Bilsen M,and Schroen BLong non-coding RNAs in the failing heart and vasculature[J].Noncoding RNA Res,2018,3(3):118-130.
[5]Zampetaki A,Albrecht A,and Steinhofel KLong Non-coding RNA Structure and Function:Is There a Link?[J].Front Physiol,2018,9:1201.
[6]Kataoka M,Wang DZ.Noncoding RNAs in Cardiovascular Disease[M]//Etiology and Morphogenesis of Congenital Heart Disease.Springer Japan,2016:313-317.
[7]Lu YW,Wang DZ.Non-coding RNA in Ischemic and Non-ischemic Cardiomyopathy[J].Curr Cardiol Rep,2018,20(11):115.
[8]Peters T,Hermans-Beijnsberger S,Beqqali A,et al.Long Non-Coding RNA Malat-1 Is Dispensable during Pressure Overload-Induced Cardiac Remodeling and Failure in Mice[J].PLoS One,2016,11(2):e0150236.
[9]Viereck J,Kumarswamy R,Foinquinos A,et al.Long noncoding RNAChast promotes cardiac remodeling[J].Sci Transl Med,2016,8(326):326ra322.
[10]Boeckel JN,Perret MF,Glaser SF,et al.Identification and regulation of the long non-coding RNA Heat2 in heart failure[J].J Mol Cell Cardiol,2018,126:13-22.
[11]Wang K,Long B,Zhou LY,et al.CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation[J].Nat Commun,2014,5:3596.
[12]Wang K,Liu F,Zhou LY,et al.The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489[J].Circ Res,2014,114(9):1377-1388.
[13]Leung A,Trac C,Jin W,et al.Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells[J].Circ Res,2013,113(3):266-278.
[14]Qiu JJ,Lin YY,Ding JX,et al.Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer[J].Int J Oncol,2015,46(6):2497-2505.